Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer

Item

http://www.wikidata.org/entity/Q37235047

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer

@en

Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.

@nl

type

Item

label

Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer

@en

Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.

@nl

prefLabel

Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer

@en

Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.

@nl

P1476

Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer

@en

P2093

A A Forastiere

http://www.w3.org/2001/XMLSchema#string

B Burtness

http://www.w3.org/2001/XMLSchema#string

B Egleston

http://www.w3.org/2001/XMLSchema#string

J Lacy

http://www.w3.org/2001/XMLSchema#string

J R Murren

http://www.w3.org/2001/XMLSchema#string

L Thomas

http://www.w3.org/2001/XMLSchema#string

M Gibson

http://www.w3.org/2001/XMLSchema#string

M Quintanilla

http://www.w3.org/2001/XMLSchema#string

R Mehra

http://www.w3.org/2001/XMLSchema#string

R Sipples

http://www.w3.org/2001/XMLSchema#string

P2860

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s.

Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.

Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma.

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.

Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.

P304

1242-1248

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDN787

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24415532

http://www.w3.org/2001/XMLSchema#string

P698

19429872

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2699385

http://www.w3.org/2001/XMLSchema#string